Curcumin and long-chain Omega-3 polyunsaturated fatty acids for Prevention of type 2 Diabetes (COP-D): Study protocol for a randomised controlled trial

Trials

Volumn 17, Issue 1, 2016, Pages

  Thota, Rohith N ^a   Acharya, Shamasunder H ^b   Abbott, Kylie A ^a   Garg, Manohar L ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Curcumin; Docosahexaenoic acid; Eicosapentaenoic acid; Inflammation; Insulin sensitivity; Omega 3 fatty acids; Prediabetes and type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CURCUMIN; FATTY ACID DERIVATIVE; FISH OIL; GLUCOSE; HEMOGLOBIN A1C; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; LEPTIN; LIPID; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; AUTACOID; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ADVERSE DRUG REACTION; AGED; ANTHROPOMETRY; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; BODY COMPOSITION; CLINICAL PROTOCOL; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FACTORIAL DESIGN; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICAL PARAMETERS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEW SOUTH WALES; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS; BLOOD GLUCOSE; BODY COMPOSITION; CLINICAL PROTOCOLS; CURCUMIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MALE; MIDDLE AGED; NEW SOUTH WALES; PREDIABETIC STATE; RESEARCH DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84999287105     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1702-9     Document Type: Article

References (62)

1. Ahima RS. Digging deeper into obesity. J Clin Invest. 2011;121(6):2076-9.
2. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249-57.
3. Whaley-Connell A, Sowers JR. Indices of obesity and cardiometabolic risk. Hypertension. 2011;58(6):991-3.
4. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378(9786):169-81.
5. International Diabetes Federation Diabetic Atlas 2015;7th edition. http://www.diabetesatlas.org/resources/2015-atlas.html.
6. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-90.
7. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6.
8. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, et al. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke. 2007;38(4):1154-60.
9. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30(5):1241-7.
10. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension. 1995;26(6):869-79.
11. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med. 2009;26(12):1185-92.
12. Karunakaran U, Kim H-J, Kim J-Y, Lee I-K. Guards and culprits in the endoplasmic reticulum: glucolipotoxicity and β-cell failure in type II diabetes. Exp Diabetes Res. 2012;2012:9.
13. Robertson RP, Harmon J, Tran PO, Poitout V. β-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53:S119-24.
14. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107.
15. DeFronzo RA, Abdul-Ghani MA. Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96(8):2354-66.
16. Ferrannini E, Gastaldelli A, Iozzo P. Pathophysiology of prediabetes. Med Clin North Am. 2011;95(2):327-39. vii-viii.
17. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130-9.
18. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753-9.
19. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
20. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289-97.
21. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-50.
22. Hommelberg PP, Langen RC, Schols AM, Mensink RP, Plat J. Inflammatory signaling in skeletal muscle insulin resistance: green signal for nutritional intervention? Curr Opin Clin Nutr Metab Care. 2010;13(6):647-55.
23. Bahadoran Z, Mirmiran P, Azizi F. Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. J Diabetes Metab Disord. 2013;12(1):1-9.
24. Swamy MV, Citineni B, Patlolla JM, Mohammed A, Zhang Y, Rao CV. Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer. 2008;60 Suppl 1:81-9.
25. Siddiqui RA, Harvey KA, Walker C, Altenburg J, Xu Z, Terry C, et al. Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice. BMC Cancer. 2013;13:418.
26. Altenburg JD, Bieberich AA, Terry C, Harvey KA, Vanhorn JF, Xu Z, et al. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer. 2011;11:149.
27. Dutta D, Mondal SA, Choudhuri S, Maisnam I, Hasanoor Reza AH, Bhattacharya B, et al. Vitamin-D supplementation in prediabetes reduced progression to type 2 diabetes and was associated with decreased insulin resistance and systemic inflammation: an open label randomized prospective study from Eastern India. Diabetes Res Clin Pract. 2014;103(3):e18-23.
28. Sollid ST, Hutchinson MY, Fuskevag OM, Figenschau Y, Joakimsen RM, Schirmer H, et al. No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with prediabetes. Diabetes Care. 2014;37(8):2123-31.
29. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008;149(7):3549-58.
30. Jimenez-Flores LM, Lopez-Briones S, Macias-Cervantes MH, Ramirez-Emiliano J, Perez-Vazquez V. A PPARgamma, NF-kappaB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db/db mice liver. Molecules. 2014;19(6):8289-302.
31. Kuo JJ, Chang HH, Tsai TH, Lee TY. Curcumin ameliorates mitochondrial dysfunction associated with inhibition of gluconeogenesis in free fatty acid-mediated hepatic lipoapoptosis. Int J Mol Med. 2012;30(3):643-9.
32. Braun M, Ramracheya R, Bengtsson M, Zhang Q, Karanauskaite J, Partridge C, et al. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes. 2008;57(6):1618-28.
33. Balamurugan AN, Akhov L, Selvaraj G, Pugazhenthi S. Induction of antioxidant enzymes by curcumin and its analogues in human islets: implications in transplantation. Pancreas. 2009;38(4):454-60.
34. Akinkuolie AO, Ngwa JS, Meigs JB, Djoussé L. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr. 2011;30(6):702-7.
35. De Caterina R, Madonna R, Bertolotto A, Schmidt EB. n-3 fy acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care. 2007;30(4):1012-26.
36. Mouratoff GJ, Scott EM. Diabetes mellitus in Eskimos after a decade. JAMA. 1973;226(11):1345-6.
37. Burrows NR, Geiss LS, Engelgau MM, Acton KJ. Prevalence of diabetes among Native Americans and Alaska Natives, 1990-1997: an increasing burden. Diabetes Care. 2000;23(12):1786-90.
38. Simonsen T, Vartun A, Lyngmo V, Nordoy A. Coronary heart disease, serum lipids, platelets and dietary fish in two communities in northern Norway. Acta Med Scand. 1987;222(3):237-45.
39. Patel PS, Sharp SJ, Luben RN, Khaw K-T, Bingham SA, Wareham NJ, et al. Association between type of dietary fish and seafood intake and the risk of incident type 2 diabetes: the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort study. Diabetes Care. 2009;32(10):1857-63.
40. Nanri A, Mizoue T, Noda M, Takahashi Y, Matsushita Y, Poudel-Tandukar K, et al. Fish intake and type 2 diabetes in Japanese men and women: the Japan Public Health Center-based Prospective Study. Am J Clin Nutr. 2011;94(3):884-91.
41. Takkunen MJ, Schwab US, de Mello VD, Eriksson JG, Lindstrom J, Tuomilehto J, et al. Longitudinal associations of serum fatty acid composition with type 2 diabetes risk and markers of insulin secretion and sensitivity in the Finnish Diabetes Prevention Study. Eur J Nutr. 2015;55(3):967-79.
42. Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia. 2006;49(2):394-7.
43. Awada M, Meynier A, Soulage CO, Hadji L, Geloen A, Viau M, et al. n-3 PUFA added to high-fat diets affect differently adiposity and inflammation when carried by phospholipids or triacylglycerols in mice. Nutr Metab. 2013;10(1):23.
44. Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Vecka M, et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids. 2004;39(12):1177-85.
45. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci. 1997;94(9):4312-7.
46. Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA, et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab. 2009;296(3):E480-9.
47. Oster RT, Tishinsky JM, Yuan Z, Robinson LE. Docosahexaenoic acid increases cellular adiponectin mRNA and secreted adiponectin protein, as well as PPARgamma mRNA, in 3T3-L1 adipocytes. Appl Physiol Nutr Metab. 2010;35(6):783-9.
48. Tishinsky JM, Ma DW, Robinson LE. Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARgamma-dependent manner in human adipocytes. Obesity (Silver Spring, MD). 2011;19(2):262-8.
49. Madsen L, Petersen RK, Kristiansen K. Regulation of adipocyte differentiation and function by polyunsaturated fatty acids. Biochim Biophys Acta. 2005;1740(2):266-86.
50. Lam YY, Hatzinikolas G, Weir JM, Janovska A, McAinch AJ, Game P, et al. Insulin-stimulated glucose uptake and pathways regulating energy metabolism in skeletal muscle cells: the effects of subcutaneous and visceral fat, and long-chain saturated, n-3 and n-6 polyunsaturated fatty acids. Biochim Biophys Acta. 2011;1811(7-8):468-75.
51. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW. Influence of dietary fat composition on development of insulin resistance in rats: relationship to muscle triglyceride and ω-3 fatty acids in muscle phospholipid. Diabetes. 1991;40(2):280-9.
52. Aas V, Rokling-Andersen MH, Kase ET, Thoresen GH, Rustan AC. Eicosapentaenoic acid (20:5 n-3) increases fatty acid and glucose uptake in cultured human skeletal muscle cells. J Lipid Res. 2006;47(2):366-74.
53. Lanza IR, Blachnio-Zabielska A, Johnson ML, Schimke JM, Jakaitis DR, Lebrasseur NK, et al. Influence of fish oil on skeletal muscle mitochondrial energetics and lipid metabolites during high-fat diet. Am J Physiol Endocrinol Metab. 2013;304(12):E1391-403.
54. Luostarinen R, Saldeen T. Dietary fish oil decreases superoxide generation by human neutrophils: relation to cyclooxygenase pathway and lysosomal enzyme release. Prostaglandins Leukot Essent Fatty Acids. 1996;55(3):167-72.
55. Fisher M, Levine PH, Weiner BH, Johnson MH, Doyle EM, Ellis PA, et al. Dietary n-3 fatty acid supplementation reduces superoxide production and chemiluminescence in a monocyte-enriched preparation of leukocytes. Am J Clin Nutr. 1990;51(5):804-8.
56. Babcock TA, Novak T, Ong E, Jho DH, Helton WS, Espat NJ. Modulation of lipopolysaccharide-stimulated macrophage tumor necrosis factor-alpha production by omega-3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10. J Surg Res. 2002;107(1):135-9.
57. Lo C-J, Chiu KC, Fu M, Lo R, Helton S. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NFΚB activity. J Surg Res. 1999;82(2):216-21.
58. Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ. NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol. 2003;284(1):L84-9.
59. Haghiac M, Yang X-h, Presley L, Smith S, Dettelback S, Minium J, et al. Dietary omega-3 fatty acid supplementation reduces inflammation in obese pregnant women: a randomized double-blind controlled clinical trial. PLoS One. 2015;10(9):e0137309.
60. Qin Y, Zhou Y, Chen S-H, Zhao X-L, Ran L, Zeng X-L, et al. Fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin E2 in nonalcoholic fatty liver disease associated with hyperlipidemia: a randomized clinical trial. PLoS One. 2015;10(7):e0133496.
61. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687-98.
62. Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity. 2013;38(6):1154-63.